Gene expression profiling of Ewing sarcoma tumours reveals the prognostic importance of tumour-stromal interactions: A report from the Children's Oncology Group

Journal of Pathology: Clinical Research

Volumn 1, Issue 2, 2015, Pages 83-94

  Volchenboum, Samuel L ^a   Andrade, Jorge ^a   Huang, Lei ^a   Barkauskas, Donald A ^b   Krailo, Mark ^b   Womer, Richard B ^c   Ranft, Andreas ^d   Potratz, Jenny ^d   Dirksen, Uta ^d   Triche, Timothy J ^b   Lawlor, Elizabeth R ^e,f  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e UNIVERSITY OF MICHIGAN   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Ewing sarcoma; Gene expression profiling; Prognostic signature

Indexed keywords

CHEMOKINE; INTEGRIN;

ADOLESCENT; ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMOKINE GENE; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; EVENT FREE SURVIVAL; EWING SARCOMA; FEMALE; GENE EXPRESSION PROFILING; GENE SIGNATURE; GENETIC ASSOCIATION; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; INFANT; INTEGRIN GENE; MALE; MOLECULAR GENETICS; MOLECULAR INTERACTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RNA ANALYSIS; SURVIVAL TIME; TUMOR MICROENVIRONMENT; VALIDATION PROCESS;

EID: 84960332668     PISSN: None     EISSN: 20564538     Source Type: Journal    
DOI: 10.1002/cjp2.9     Document Type: Article

References (52)

1. Balamuth NJ, Womer RB. Ewing's sarcoma. Lancet Oncol 2010; 11: 184-192.
2. Womer RB, West DC, Krailo MD, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol 2012; 30: 4148-4154.
3. Le Deley MC, Paulussen M, Lewis I, et al. Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial. J Clin Oncol 2014; 32: 2440-2448.
4. Ginsberg JP, Goodman P, Leisenring W, et al. Long-term survivors of childhood Ewing sarcoma: report from the childhood cancer survivor study. J Natl Cancer Inst 2010; 102: 1272-1283.
5. Youn P, Milano MT, Constine LS, et al. Long-term cause-specific mortality in survivors of adolescent and young adult bone and soft tissue sarcoma: a population-based study of 28, 844 patients. Cancer 2014; 120: 2334-2342.
6. Shukla N, Schiffman J, Reed D, et al. Biomarkers in Ewing sarcoma: the promise and challenge of personalized medicine. A report from the children's oncology group. Front Oncol 2013; 3: 141.
7. Carlson JJ, Roth JA. The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis. Breast Cancer Res Treat 2013; 141: 13-22.
8. Erho N, Crisan A, Vergara IA, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One 2013; 8: e66855.
9. Trinquand A, Tanguy-Schmidt A, Ben Abdelali R, et al. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a group for research in adult acute lymphoblastic leukemia study. J Clin Oncol 2013; 31: 4333-4342.
10. Asgharzadeh S, Pique-Regi R, Sposto R, et al. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst 2006; 98: 1193-1203.
11. Oberthuer A, Hero B, Berthold F, et al. Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol 2010; 28: 3506-3515.
12. Stricker TP, Morales La Madrid A, Chlenski A, et al. Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounter system. Mol Oncol 2014; 8: 669-678.
13. Davicioni E, Anderson JR, Buckley JD, et al. Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the children's oncology group. J Clin Oncol 2010; 28: 1240-1246.
14. Wilson RA, Teng L, Bachmeyer KM, et al. A novel algorithm for simplification of complex gene classifiers in cancer. Cancer Res 2013; 73: 5625-5632.
15. Missiaglia E, Williamson D, Chisholm J, et al. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol 2012; 30: 1670-1677.
16. Cleaver AL, Beesley AH, Firth MJ, et al. Gene-based outcome prediction in multiple cohorts of pediatric T-cell acute lymphoblastic leukemia: a Children's Oncology Group study. Mol Cancer 2010; 9: 105.
17. Kang H, Chen IM, Wilson CS, et al. Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. Blood 2010; 115: 1394-1405.
18. Bennani-Baiti IM, Cooper A, Lawlor ER, et al. Intercohort gene expression co-analysis reveals chemokine receptors as prognostic indicators in Ewing's sarcoma. Clin Cancer Res 2010; 16: 3769-3778.
19. Ohali A, Avigad S, Zaizov R, et al. Prediction of high risk Ewing's sarcoma by gene expression profiling. Oncogene 2004; 23: 8997-9006.
20. Schaefer KL, Eisenacher M, Braun Y, et al. Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. Eur J Cancer 2008; 44: 699-709.
21. Scotlandi K, Remondini D, Castellani G, et al. Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome. J Clin Oncol 2009; 27: 2209-2216.
22. Paulussen M, Craft AW, Lewis I, et al. Results of the EICESS-92 study: two randomized trials of Ewing's sarcoma treatment-cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol 2008; 26: 4385-4393.
23. van Doorninck JA, Ji L, Schaub B, et al. Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol 2010; 28: 1989-1994.
24. Peter M, Gilbert E, Delattre O. A multiplex real-time pcr assay for the detection of gene fusions observed in solid tumors. Lab Invest 2001; 81: 905-912.
25. Lockstone HE. Exon array data analysis using Affymetrix power tools and R statistical software. Brief Bioinform 2011; 12: 634-644.
26. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007; 8: 118-127.
27. Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 2010; 26: 1572-1573.
28. Smyth GK. Limma: linear models for microarray data. In Gentleman R, Carey, V., Dudoit., S., Irizarry R., Huber W. (eds.), Bioinformatics and Computational Biology Solutions using R and Bioconductor. Springer: New York 2005; 397-420.
29. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995; 57: 289-300.
30. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44-57.
31. Starmans MHW, Fung G, Steck H, et al. A simple but highly effective approach to evaluate the prognostic performance of gene expression signatures. PLoS One 2011; 6: e28320.
32. Janitza S, Strobl C, Boulesteix A-L. An AUC-based permutation variable importance measure for random forests. BMC Bioinform 2013; 14: 119.
33. Breiman L. Random forests. Mach Learn 2001; 45: 5-32.
34. Cortes C, Vapnik V. Support-vector networks. Mach Learn 1995; 20: 273-297.
35. Bishop CM. Pattern Recognition and Machine Learning. Springer, New York, USA, 2006.
36. Kuhn M. Building predictive models in R using the caret package. J Stat Softw 2008; 28: 1-26.
37. Bishop YM, Fienberg SE, Holland PW. Discrete Multivariate Analysis. MIT press: Cambridge, MA, 1975.
38. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. Wiley: New York, 1980.
39. Borinstein SC, Beeler N, Block JJ, et al. A decade in banking Ewing sarcoma: a report from the Children's Oncology Group. Front Oncol 2013; 3: 57.
40. Marino-Enriquez A, Fletcher CD. Round cell sarcomas-biologically important refinements in subclassification. Int J Biochem Cell Biol 2014; 53: 493-504.
41. Specht K, Sung YS, Zhang L, et al. Distinct transcriptional signature and immunoprofile of CIC-DUX4 fusion-positive round cell tumors compared to EWSR1-rearranged ewing sarcomas: further evidence toward distinct pathologic entities. Genes Chromosomes Cancer 2014; 53: 622-633.
42. Luo W, Gangwal K, Sankar S, et al. GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance. Oncogene 2009; 28: 4126-4132.
43. Abdel-Wahab O, Mullally A, Hedvat C, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009; 114: 144-147.
44. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18: 553-567.
45. Shieh AD, Hung YS. Detecting outlier samples in microarray data. Stat Appl Genet Mol Biol 2009; 8: 1-24.
46. Cooper A, van Doorninck J, Ji L, et al. Ewing tumors that do not overexpress BMI-1 are a distinct molecular subclass with variant biology: a report from the Children's Oncology Group. Clin Cancer Res 2011; 17: 56-66.
47. Crompton BD, Carlton AL, Thorner AR, et al. High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in Ewing sarcoma. Cancer Res 2013; 73: 2873-2883.
48. Mendoza-Naranjo A, El-Naggar A, Wai DH, et al. ERBB4 confers metastatic capacity in Ewing sarcoma. EMBO Mol Med 2013; 5: 1019-1034.
49. Berghuis D, Schilham MW, Santos SJ, et al. The CXCR4-CXCL12 axis in Ewing sarcoma: promotion of tumor growth rather than metastatic disease. Clin Sarcoma Res 2012; 2: 24.
50. Jin Z, Zhao C, Han X, et al. Wnt5a promotes ewing sarcoma cell migration through upregulating CXCR4 expression. BMC Cancer 2012; 12: 480.
51. Hamdan R, Zhou Z, Kleinerman ES. Blocking SDF-1alpha/CXCR4 downregulates PDGF-B and inhibits bone marrow-derived pericyte differentiation and tumor vascular expansion in Ewing tumors. Mol Cancer Ther 2014; 13: 483-491.
52. Krook MA, Nicholls LA, Scannell CA, et al. Stress-induced CXCR4 promotes migration and invasion of ewing sarcoma. Mol Cancer Res 2014; 12: 953-964.